Cargando…
The Clinical Impact of 21-Gene Recurrence Score on Treatment Decisions for Patients with Hormone Receptor-Positive Early Breast Cancer in Korea
PURPOSE: The 21-gene (Oncotype DX) recurrence score (RS) assay is useful in predicting the benefits of adjuvant chemotherapy for early breast cancer patients and is widely used in Western countries. However, to date, it has not gained much popularity in East Asia. We analyzed the results from five i...
Autores principales: | Lee, Moo Hyun, Han, Wonshik, Lee, Jeong Eon, Kim, Ku Sang, Park, Heeseung, Kim, Jongjin, Bae, Soo Youn, Shin, Hyun Joo, Lee, Jong Won, Lee, Eun Sook |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Cancer Association
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398124/ https://www.ncbi.nlm.nih.gov/pubmed/25381828 http://dx.doi.org/10.4143/crt.2013.223 |
Ejemplares similares
-
Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score
por: Paik, Soonmyung, et al.
Publicado: (2021) -
Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
por: Lee, Eun-Shin, et al.
Publicado: (2016) -
The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database
por: Choi, In Sil, et al.
Publicado: (2020) -
Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database
por: Jung, Jiwoong, et al.
Publicado: (2022) -
Association between Ultrasound Features and the 21-Gene Recurrence Score Assays in Patients with Oestrogen Receptor-Positive, HER2-Negative, Invasive Breast Cancer
por: Chae, Eun Young, et al.
Publicado: (2016)